MedTrace Logo

Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion

NCT02322229 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2018-08-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.

Conditions

  • Vitreomacular Traction
  • Vitreomacular Adhesion

Interventions

DRUG

Ocriplasmin 0.125 mg in a 0.1 mL volume

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Associate Dir of Operations, Ophthalmology, GMA · Alcon, A Novartis Division

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-26
Primary Completion
2015-12-11
Completion
2016-05-09

Countries

  • Australia

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02322229 on ClinicalTrials.gov